Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$40.00 +0.9%	$34.98	$23.42 ▼ $62.58	$2.30B	0.73	646,375 shs	529,138 shs
BCAX Bicara Therapeutics	$11.75 -1.5%	$10.63	$7.80 ▼ $28.09	$650.62M	N/A	522,814 shs	204,552 shs
BHC Bausch Health Cos	$6.77 -0.2%	$5.76	$4.25 ▼ $9.85	$2.51B	0.41	1.47 million shs	754,167 shs
RXRX Recursion Pharmaceuticals	$6.49 +3.7%	$5.12	$3.79 ▼ $12.36	$2.54B	0.91	33.10 million shs	23.55 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-2.24%	-1.73%	+18.64%	+34.63%	-17.72%
BCAX Bicara Therapeutics	+1.19%	+2.40%	+25.45%	-17.95%	+1,192,999,900.00%
BHC Bausch Health Cos	+1.96%	+4.47%	+9.36%	+25.00%	+16.61%
RXRX Recursion Pharmaceuticals	-2.64%	+13.41%	+19.92%	+9.25%	-19.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3542 of 5 stars	3.4	3.0	4.3	2.0	0.8	1.9
BCAX Bicara Therapeutics	2.0924 of 5 stars	3.5	0.0	0.0	2.7	0.8	0.6
BHC Bausch Health Cos	3.3509 of 5 stars	0.9	4.0	4.0	0.6	3.3	1.9
RXRX Recursion Pharmaceuticals	0.7941 of 5 stars	1.2	2.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$57.33	43.33% Upside
BCAX Bicara Therapeutics	3.00	Buy	$31.86	171.14% Upside
BHC Bausch Health Cos	1.80	Reduce	$7.38	9.02% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	7.86% Upside

Current Analyst Ratings Breakdown

Latest BCAX, RXRX, BHC, and AGIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00
7/8/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
7/3/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
5/23/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$8.00
5/23/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
5/16/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $41.00
5/6/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
5/2/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$74.00 ➝ $71.00
5/2/2025	BHC Bausch Health Cos	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$8.50 ➝ $10.00

(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	63.47	N/A	N/A	$27.02 per share	1.48
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$9.04 per share	N/A
BHC Bausch Health Cos	$9.63B	0.26	$7.69 per share	0.88	($0.89) per share	-7.60
RXRX Recursion Pharmaceuticals	$58.84M	44.84	N/A	N/A	$2.61 per share	2.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.24	3.56	N/A	N/A	1,798.26%	-2.75%	-2.52%	7/31/2025 (Estimated)
BCAX Bicara Therapeutics	-$68M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/12/2025 (Estimated)
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.45	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.77	N/A	N/A	N/A	-961.32%	-74.70%	-54.02%	8/6/2025 (Estimated)

Latest BCAX, RXRX, BHC, and AGIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RXRX Recursion Pharmaceuticals	-$0.34	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	BCAX Bicara Therapeutics	-$0.54	N/A	N/A	N/A	N/A	N/A
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	N/A	N/A	N/A	$9.46 million	N/A
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.9320	N/A	N/A	N/A	$2.47 billion	N/A
5/13/2025	Q1 2025	BCAX Bicara Therapeutics	-$0.40	-$0.68	-$0.28	-$0.68	N/A	N/A
5/5/2025	Q1 2025	RXRX Recursion Pharmaceuticals	-$0.44	-$0.50	-$0.06	-$0.50	$18.12 million	$14.75 million
5/1/2025	Q1 2025	AGIO Agios Pharmaceuticals	-$1.80	-$1.55	+$0.25	-$1.55	$9.86 million	$8.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	18.50	17.93
BCAX Bicara Therapeutics	N/A	24.62	24.62
BHC Bausch Health Cos	N/A	1.35	0.97
RXRX Recursion Pharmaceuticals	0.02	4.11	4.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
BCAX Bicara Therapeutics	N/A
BHC Bausch Health Cos	78.65%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
BCAX Bicara Therapeutics	15.50%
BHC Bausch Health Cos	8.05%
RXRX Recursion Pharmaceuticals	8.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	57.92 million	55.43 million	Optionable
BCAX Bicara Therapeutics	32	54.54 million	46.08 million	N/A
BHC Bausch Health Cos	20,700	370.09 million	340.29 million	Optionable
RXRX Recursion Pharmaceuticals	400	406.49 million	372.23 million	Optionable

BCAX, RXRX, BHC, and AGIO Headlines

Recent News About These Companies

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

July 25 at 1:53 PM | benzinga.com

RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?

July 25 at 12:36 PM | zacks.com

Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note

July 23 at 6:51 PM | zacks.com

Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?

July 23 at 11:06 AM | zacks.com

Recursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 Earnings

July 22 at 4:54 PM | insidermonkey.com

Pier 88 Investment Partners LLC Sells 66,940 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

July 22 at 11:41 AM | marketbeat.com

Brokerages Set Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) PT at $7.00

July 22 at 2:40 AM | americanbankingnews.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Time to Buy?

July 21, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock?

July 21, 2025 | zacks.com

Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia

July 21, 2025 | finance.yahoo.com

Q2 Earnings Estimate for RXRX Issued By Leerink Partnrs

July 21, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Sees 14% Price Surge Over Last Month

July 20, 2025 | finance.yahoo.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Recommendation of "Hold" from Analysts

July 19, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 9.4% - Here's Why

July 18, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Rises Higher Than Market: Key Facts

July 17, 2025 | zacks.com

Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock

July 17, 2025 | zacks.com

Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

July 16, 2025 | zacks.com

D.A. Davidson & CO. Raises Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

July 11, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

July 10, 2025 | zacks.com

Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating

July 10, 2025 | msn.com

Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia

July 9, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX, RXRX, BHC, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$40.00 +0.35 (+0.88%)

Closing price 04:00 PM Eastern

Extended Trading

$39.99 -0.01 (-0.02%)

As of 04:13 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Bicara Therapeutics NASDAQ:BCAX

$11.75 -0.18 (-1.51%)

Closing price 04:00 PM Eastern

Extended Trading

$11.74 -0.01 (-0.04%)

As of 04:11 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Bausch Health Cos NYSE:BHC

$6.76 -0.02 (-0.22%)

Closing price 03:59 PM Eastern

Extended Trading

$6.84 +0.08 (+1.18%)

As of 08:00 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Recursion Pharmaceuticals NASDAQ:RXRX

$6.49 +0.23 (+3.67%)

Closing price 04:00 PM Eastern

Extended Trading

$6.51 +0.02 (+0.31%)

As of 07:59 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time